'NSF's Education Courses, Like The APPQM, Change The Way People Think'

Medicines are only as good as the people making them, points out Martin Lush, Global Vice President, Pharma Biotech and Medical Devices, NSF Health Sciences. In an email interaction with Viveka Roychowdhury, he explains how the NSF-IDMA‘Advanced Program in Pharmaceutical Quality Management (APPQM) will provide companies with ‘rounded’ professionals who will help senior management sleep easier at night

- Vivek Roychowdhury

What does the NSF certification mark mean to the pharma and biotech industries?

NSF was established in 1947 to improve global health. It is an internationally recognised, respected and trusted certifying body. What does this mean for the Indian pharma biotech industry and those attending NSF IDMA APPQM? It means those who pass the course's assessments have met the standards required and have the knowledge to improve their companies’ regulatory compliance, competitive advantage and reduce risk.

What are the services NSF International provides to this sector?

Our objective is to leave clients better off than when we found them. More profitable, more compliant and more resilient (future proofed). Our services include consultancy support, benchmarking, education, auditing and remediation. But with a difference. Our education courses, like the APPQM, change the way people think. Our auditing and consultancy services help simplify operations to improve efficiency as well as compliance. And when clients get into trouble with regulatory agencies our remediation services leave our clients stronger, not weaker. We just treat our clients in the way we would like to be treated. With humility and respect.

NSF International's staff is a agency staff and experienced industry professionals and in fact provides training to regulators from eight regulatory agencies, including agencies in the US and the EU. Can you give us a sense of how this unique edge translates into consulting, course content and classroom insights, etc. for your clients in the pharma sector?